Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Human Monoclonal MAP2K7 Primary Antibody for ICC, FACS - ABIN969271
Yoshizawa, Hammaker, Sweeney, Boyle, Firestein: Synoviocyte innate immune responses: I. Differential regulation of interferon responses and the JNK pathway by MAPK kinases. in Journal of immunology (Baltimore, Md. : 1950) 2008
Show all 2 Pubmed References
In the coBRIM phase III trial, the addition of cobimetinib, an MEK (show MAP2K1 Antibodies) inhibitor, to vemurafenib, a BRAF (show BRAF Antibodies) inhibitor, significantly improved progression-free survival [hazard ratio (HR), 0.58; P < 0.0001] and overall survival (HR, 0.70; P = 0.005) in advanced BRAF (show BRAF Antibodies)-mutated melanoma. Here, we report on the incidence, course, and management of key adverse events (AEs (show AES Antibodies)) in the coBRIM study
the p.Glu116Lys rare variant in MAP2K7 predisposes its carriers to develop COPD (show ARCN1 Antibodies), which would provide a useful genetic biomarker for COPD (show ARCN1 Antibodies) susceptibility in Chinese.
Combination BRAF (show BRAF Antibodies) and MEK (show MAP2K1 Antibodies) inhibition has also been shown to improve overall survival in patients with V600E-mutated melanoma. Responses to therapy are often rapid, and treatment is not associated with immune-related adverse events.
Our findings indicate that GADD45 (show GADD45A Antibodies) essentially suppresses the MKK7-JNK (show MAPK8 Antibodies) pathway and suggest that differentially expressed GADD45 (show GADD45A Antibodies) family members fine-tune stress-inducible JNK (show MAPK8 Antibodies) activity.
The latter insight is likely to promote the production of allosteric MAP2K7 inhibitors.
MEK activation cooperates with Cdkn2a and Pten inactivation to induce melanoma
MKK7 undergoes neddylation in human breast cancer cells
In an Eastern Chinese population, carriers of MAP2K7 rs3679T variant genotypes had an increased risk of NSCLC.
Therefore, EGF (show EGF Antibodies) is suggested to induce E-cadherin (show CDH1 Antibodies) down-regulation at the transcriptional level through the MEK (show MAP2K1 Antibodies)/ERK (show EPHB2 Antibodies) pathway, which might result in, at least in part, the induction of cellular morphological changes and cell migration in LoVo cells.
combined pan-RAF and MEK inhibition can overcome intrinsic and acquired resistance to single-agent RAF/MEK inhibition, supporting dual pan-RAF and MEK inhibition as a novel therapeutic strategy for BRAF- and KRAS-mutant cancers
High Map2k7 expression is associated with T-cell acute lymphoblastic leukemia.
The loss of mkk4 (show MAP2K4 Antibodies) and mkk7 locks damaged exocrine cells in a permanently de-differentiated state.
Arrestin-3 (show ARRB2 Antibodies) directly interacts with MKK7 and promotes JNK3alpha2 phosphorylation by both MKK4 (show MAP2K4 Antibodies) and MKK7 in vitro as well as in intact cells.
MKK7 is specifically phosphorylated in the neurite shaft which triggers Map1b (show MAP1B Antibodies) phosphorylation to regulate microtubule bundling leading to neurite elongation.
Data indicate that mitogen activated protein kinase kinase 7 (MKK7) plays a critical regulatory role in the c-Jun N-terminal kinase pathway in a murine model of rheumatoid arthritis.
a novel function for the stress kinase MKK7 as a regulator of the circadian clock in mammalian cells at steady state.
Distinct signaling properties of mitogen-activated protein kinase kinases 4 (MKK4) and 7 (MKK7) in embryonic stem cell (ESC) differentiation.
MKK4 (show MAP2K4 Antibodies)/7 and JNK1 (show MAPK8 Antibodies)/2 played regulatory role in cytoskeleton reorganization during vaccinia virus infection.
This study demonistrated that Stress-activated protein kinase (show CDK7 Antibodies) MKK7 regulates axon elongation in the developing cerebral cortex.
The results reveal an essential role of MKK7 in cardiomyocytes for protecting the heart from hypertrophic insults thereby preventing the transition to heart failure.
The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase specifically activates MAPK8/JNK1 and MAPK9/JNK2, and this kinase itself is phosphorylated and activated by MAP kinase kinase kinases including MAP3K1/MEKK1, MAP3K2/MEKK2,MAP3K3/MEKK5, and MAP4K2/GCK. This kinase is involved in the signal transduction mediating the cell responses to proinflammatory cytokines, and environmental stresses. Multiple alternatively spliced transcript variants encoding distinct isoforms have been found, but only one transcript variant has been supported and defined.
mitogen-activated protein kinase kinase 7
, JNK kinase 2
, JNK-activating kinase 2
, JNKK 2
, MAP kinase kinase 7
, MAPK/ERK kinase 7
, MAPKK 7
, MEK 7
, c-Jun N-terminal kinase kinase 2
, dual specificity mitogen-activated protein kinase kinase 7
, SAPK kinase 4
, stress-activated protein kinase kinase 4
, mitogen activated protein kinase kinase 7
, protein kinase, mitogen activated, kinase 7